<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992417</url>
  </required_header>
  <id_info>
    <org_study_id>OBS15990</org_study_id>
    <nct_id>NCT03992417</nct_id>
  </id_info>
  <brief_title>Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)</brief_title>
  <acronym>GLOBOSTAD</acronym>
  <official_title>A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world&#xD;
      setting, with respect to their medical history, socio-demographic and disease&#xD;
      characteristics, and prior and concomitant treatments of AD&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason&#xD;
           for initiation of new treatments, concomitant therapies, treatment durations and reasons&#xD;
           for discontinuation and/or switching)&#xD;
&#xD;
        -  To assess the long-term effectiveness of Dupixent® in AD patients in a real-world&#xD;
           setting&#xD;
&#xD;
        -  To assess comorbid atopic conditions and effects of treatment in comorbid atopic&#xD;
           conditions in patients who receive Dupixent® for AD&#xD;
&#xD;
        -  To collect safety data on study participants&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants enrolled in the study will be followed for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>60 Months</target_duration>
  <primary_outcome>
    <measure>Baseline Characteristics: Medical history</measure>
    <time_frame>Baseline to Month 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Characteristics: Socio-demographics</measure>
    <time_frame>Baseline to Month 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Characteristics: Disease characteristics</measure>
    <time_frame>Baseline to Month 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Assessment: Body Surface Area Affected (BSA) by Atopic Dermatitis</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Percentage of BSA affected by AD assessed for each major section of the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Assessment: Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Measure used in clinical practice and clinical trials to assess the severity and extent of AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Assessment: Scoring of Atopic Dermatitis (SCORAD)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Measure used in clinical practice and clinical trials to standardize the evaluation of the severity and extent of AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Pruritus Numerical Rating Scale (NRS)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Individual NRS used to rate the intensity of pruritus using a 0 to 10 numeric rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Skin Pain or Soreness NRS</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Individual NRS used to rate skin pain and soreness using a 0 to 10 NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Skin Feeling Hot NRS</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Individual NRS used to rate the sensation of skin feeling hot (burning sensation) using a 0 to 10 NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Skin Sensitivity NRS</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Individual NRS used to rate skin sensitivity using a 0 to 10 NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Sleep Disturbance NRS</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Individual NRS used to report the severity of their sleep disturbance using a 0 to 10 NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Dermatology Life Quality Index (DLQI) for adults and Children Dermatology Life Quality Index (CDLQI) for adolescents</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Juniper Asthma Control Questionnaire (ACQ-5)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Questionnaire to evaluate asthma control in participants with comorbid asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Allergic Rhinitis-Visual Analog Scale (AR-VAS)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Instrument for the documentation of symptoms and therapy monitoring in allergic rhinitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Work Productivity and Activity Impairment Questionnaire for AD (WPAI-AD) for adults and Work Productivity and Activity Impairment Questionnaire+Classroom Impairment Questions for AD (WPAI-CIQ-AD) for adolescents</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Questionnaire to assess the impact of AD on productivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Health Care Resource Utilization Questionnaire</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Questionnaire regarding hospitalization, or emergency room/urgent care center visits due to AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: 9-Item Treatment Satisfaction Questionnaire for Medication (TSQM-9)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Instrument to measure treatment satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Number of participants with at least 1 AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment: Atopic Dermatitis Control Tool (ADCT) to be collected optionally</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Questionnaire related with Atopic dermatitis control</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Dermatitis Atopic</condition>
  <arm_group>
    <arm_group_label>Participants with AD</arm_group_label>
    <description>Adult and adolescent participants with AD initiating treatment with Dupixent® for AD according to the country-specific prescribing information, as part of their usual care as determined by their physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab SAR231893 (REGN668)</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous injection</description>
    <arm_group_label>Participants with AD</arm_group_label>
    <other_name>Dupixent®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population is adult and adolescent patients (male or female, ≥12 years old), who&#xD;
        are initiating treatment with Dupixent® for AD according to the country-specific&#xD;
        prescribing information.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 12 years or older at the baseline visit. Note: Adolescent participants&#xD;
             (at least 12 years old, but less than 18 years) are eligible only after Dupixent®&#xD;
             receives the respective country's regulatory approval for use in this age group;&#xD;
&#xD;
          -  Initiating treatment with Dupixent® for AD according to the country-specific&#xD;
             prescribing information. Note: Participants may be eligible if they have already&#xD;
             initiated treatment with Dupixent® for AD within 6 months before their enrollment in&#xD;
             the registry, provided that all core baseline data required (Eczema Area and Severity&#xD;
             Index [EASI], Scoring of Atopic Dermatitis [SCORAD], body surface area [of AD&#xD;
             involvement] [BSA], Patient-Oriented Eczema Measure [POEM], and Dermatology Life&#xD;
             Quality Index [DLQI]) by the registry protocol were captured at the time of initiating&#xD;
             Dupixent® treatment and are available for entry in the registry database&#xD;
&#xD;
          -  Able to understand and complete study-related questionnaires&#xD;
&#xD;
          -  Provide signed informed consent or parental/legally acceptable representative consent&#xD;
             and/or patient assent where applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have a contraindication to the drug according to the country-specific&#xD;
             prescribing information label&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, may interfere with patient's&#xD;
             ability to participate in the study, such as short life expectancy, substance abuse,&#xD;
             severe cognitive impairment, or other co-morbidities that can predictably prevent the&#xD;
             participant patient from adequately completing the schedule of visits and assessments&#xD;
&#xD;
          -  Patients currently participating in any interventional clinical trial which modifies&#xD;
             patient care&#xD;
&#xD;
          -  Prior use of Dupixent® within 6 months of the screening visit, or within 6 months of&#xD;
             the baseline visit if screening and baseline occur on the same day&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site Argentina</name>
      <address>
        <city>Argentina</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site AUSTRALIA</name>
      <address>
        <city>Australia</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site AUSTRIA</name>
      <address>
        <city>Austria</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Belgium</name>
      <address>
        <city>Belgium</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site colombia</name>
      <address>
        <city>Colombia</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Czech Republic</name>
      <address>
        <city>Czech Republic</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Finland</name>
      <address>
        <city>Finland</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500011</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500004</name>
      <address>
        <city>Auxerre</city>
        <zip>89000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500003</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500009</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500006</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500007</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500010</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500005</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500002</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site number 2500001</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Greece</name>
      <address>
        <city>Greece</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Israel</name>
      <address>
        <city>Israel</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Italy</name>
      <address>
        <city>Italy</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Japan</name>
      <address>
        <city>Japan</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Kuwait</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Mexico</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Netherlands</name>
      <address>
        <city>Netherlands</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Norway</name>
      <address>
        <city>Norway</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Portugal</name>
      <address>
        <city>Portugal</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Russia</name>
      <address>
        <city>Russia</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Saudi Arabia</name>
      <address>
        <city>Saudi Arabia</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Spain</name>
      <address>
        <city>Spain</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Taiwan</name>
      <address>
        <city>Taiwan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site United Arab Emirates</name>
      <address>
        <city>United Arab Emirates</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Kuwait</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

